Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Online Letters: Comments and Responses

Comment on: Suissa and Azoulay. Metformin and the Risk of Cancer: Time-Related Biases in Observational Studies. Diabetes Care 2012;35:2665–2673

  1. Xilin Yang, PHD1⇑ and
  2. Juliana C.N. Chan, MD, FRCP2⇑
  1. 1Department of Epidemiology and Biostatistics School of Public Health, Tianjin Medical University, Tianjin, China
  2. 2Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China
  1. Corresponding author: Xilin Yang, yxl{at}hotmail.com, or Juliana C.N. Chan, jchan{at}cuhk.edu.hk.
Diabetes Care 2013 Jun; 36(6): e87-e87. https://doi.org/10.2337/dc12-2561
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

In a recent article in Diabetes Care, Suissa and Azoulay (1) concluded that the impressive results of the metformin-associated reduced cancer risk were due to many researchers failing to adjust for immortal time bias and not using time-dependent analysis of drug exposure. However, this conclusion is not justified since it remains controversial whether immortal time would introduce substantial bias.

We used statins and their effect on cardiovascular disease (CVD) to illustrate how different analyses could yield different results in pharmacoepidemiological studies. In a time-fixed Cox model, statin use was associated with a hazard ratio (HR) of 0.66 (95% CI 0.50–0.88) for CVD, an effect size similar to that in randomized trials despite 48% of the total follow-up time in the statin users being immortal time (i.e., without drug exposure). Herein, immortal time had introduced two sources of bias: 1) the nonexposure to statins misclassified as “exposed” that tended to inflate HR and 2) the nil risk of CVD in statin users during the immortal time periods misclassified as being at the same risk of nonusers that deflated the HR. Since these two sources of bias tended to neutralize each other, the HR of 0.66 was close to the real effect demonstrated in randomized studies (2).

On the other hand, if we used the time-dependent statin exposure analysis as proposed by Suissa (3), we obtained an HR of 1.74 (95% CI 1.30–2.31). If we further applied the immortal time-correcting formula suggested by Suissa (3), the HR was 1.47 (1.12–1.96) (2), i.e., increased CVD risk with statin use. Nevertheless, if the same immortal time periods of the statin users were added to the follow-up periods of the nonstatin users, the HR was decreased to 0.23 (0.14–0.36) (2).

Based on the recommendation of Rothman and Suissa (4), we excluded the immortal time periods among metformin users and reestimated the HR of metformin use for cancer using published data (5). By reestimating covariables at the time of initiation of metformin treatment during follow-up, we obtained a multivariable HR of 0.57 (95% CI 0.37–0.86) for cancer risk with metformin use. The additive interaction between nonuse of metformin and HDL cholesterol <1.0 mmol/L remained significant (multivariable attributable proportion due to interaction (AP): 0.48 (0.11–0.84), P < 0.05. Using this as the gold standard, we noted that time-dependent Cox model analysis yielded a multivariable HR of 0.97 (0.63–1.50) while time-fixed Cox model analysis yielded a multivariable HR of 0.40 (0.26–0.60). In other words, the HR was underestimated by 30% using time-fixed Cox model analysis and overestimated by 70% using the time-dependent Cox model.

In conclusion, our data show that immortal time bias, especially the proposed time-dependent drug exposure analysis, remains controversial. Using time-dependent drug exposure analysis to judge the scientific merits of pharmacoepidemiological studies of drug effects will only lead to more confusion rather than clarity with negative impacts on clinical practice and research. Here, we call for validation of the method using a drug with a known effect before reporting drug effects on cancer in diabetes.

Acknowledgments

J.C.N.C. is a member of the steering committees of international projects or randomized clinical trials funded by Amylin, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Lilly, Merck Sharp & Dohme, and Sanofi. She is a member of global advisory boards or expert groups or speaker’s bureau sponsored by AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Lilly, Merck Sharp & Dohme, Pfizer, and Sanofi, with honorarium and travelling support. Her institution, The Chinese University of Hong Kong (CUHK), has received research grants from Amylin, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, Impeto, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sanofi, and Takeda. All honorarium or speakers’ fees have been donated to the CUHK to support research and education in diabetes. No other potential conflicts of interest relevant to this article were reported.

  • © 2013 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

References

  1. ↵
    1. Suissa S,
    2. Azoulay L
    . Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012;35:2665–2673
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Yang XL,
    2. Ma RC,
    3. So WY,
    4. Kong AP,
    5. Xu G,
    6. Chan JC
    . Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings—what, why and how? Diabetes Obes Metab 2012;14:579–585
    OpenUrlCrossRefPubMed
  3. ↵
    1. Suissa S
    . Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008;167:492–499
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Rothman KJ,
    2. Suissa S
    . Exclusion of immortal person-time. Pharmacoepidemiol Drug Saf 2008;17:1036
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Yang X,
    2. So WY,
    3. Ma RC,
    4. et al
    . Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 2011;34:375–380
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Diabetes Care: 36 (6)

In this Issue

June 2013, 36(6)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comment on: Suissa and Azoulay. Metformin and the Risk of Cancer: Time-Related Biases in Observational Studies. Diabetes Care 2012;35:2665–2673
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Comment on: Suissa and Azoulay. Metformin and the Risk of Cancer: Time-Related Biases in Observational Studies. Diabetes Care 2012;35:2665–2673
Xilin Yang, Juliana C.N. Chan
Diabetes Care Jun 2013, 36 (6) e87; DOI: 10.2337/dc12-2561

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Comment on: Suissa and Azoulay. Metformin and the Risk of Cancer: Time-Related Biases in Observational Studies. Diabetes Care 2012;35:2665–2673
Xilin Yang, Juliana C.N. Chan
Diabetes Care Jun 2013, 36 (6) e87; DOI: 10.2337/dc12-2561
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Acknowledgments
    • References
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Comment on Khunti et al. Clinical Inertia in People With Type 2 Diabetes: A Retrospective Cohort Study of More Than 80,000 People. Diabetes Care 2013;36:3411–3417
  • Response to Comment on Khunti et al. Clinical Inertia in People With Type 2 Diabetes: A Retrospective Cohort Study of More Than 80,000 People. Diabetes Care 2013;36:3411–3417
  • Comment on Lázaro-Martínez et al. Antibiotics Versus Conservative Surgery for Treating Diabetic Foot Osteomyelitis: A Randomized Comparative Trial. Diabetes Care 2014;37:789–795
Show more Online Letters: Comments and Responses

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.